Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-cel at February Scientific Meetings
Provided By GlobeNewswire
Last update: Feb 18, 2025
– Clinical efficacy continued to deepen over time with three SLE patients in DORIS remission, the first LN patient achieving complete renal response, and the first dermatomyositis patient maintaining a major TIS improvement; each of these patients discontinued all immunosuppressants and are off steroids as of the latest follow-up –
Read more at globenewswire.com1.57
-0.13 (-7.65%)
Find more stocks in the Stock Screener
CABA Latest News and Analysis
17 days ago - ChartmillLet's have a look at the top gainers and losers one hour before the close of the markets of today's session.Keep an eye on the top gainers and losers in Wednesday's session, as they reflect the most notable price movements.
17 days ago - ChartmillTop movers analysis in the middle of the day on 2025-06-11: top gainers and losers in today's session.Curious about what's happening in today's session? Check out the latest stock movements and price changes.
17 days ago - ChartmillWhich stocks are gapping on Wednesday?Traders are paying attention to the gapping stocks in Wednesday's session. Let's dive into which stocks are experiencing notable gaps.
